384 related articles for article (PubMed ID: 30989325)
41. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
42. BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Sapelli J; Filho JS; Matias Vieira GM; Moura FL; Germano JN; de Lima VCC
Leuk Res; 2021 Nov; 110():106689. PubMed ID: 34592699
[TBL] [Abstract][Full Text] [Related]
43. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
44. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
Zhang H; Graiser M; Hutcherson DA; Dada MO; McMillan S; Ali Z; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1287-94. PubMed ID: 22370160
[TBL] [Abstract][Full Text] [Related]
46. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
47. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
48. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
49. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
Damaj G; Ivanoff S; Coso D; Ysaebert L; Choquet S; Houillier C; Parcelier A; Abarah W; Marjanovic Z; Gressin R; Garidi R; Diouf M; Gac AC; Dupuis J; Troussard X; Morschhauseur F; Ghesquières H; Soussain C;
Haematologica; 2015 Sep; 100(9):1199-206. PubMed ID: 26185174
[TBL] [Abstract][Full Text] [Related]
50. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
[TBL] [Abstract][Full Text] [Related]
51. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J; Fox CP; Valk E; Steinheber C; Fricker H; Isbell LK; Neumaier S; Okosun J; Scherer F; Ihorst G; Cwynarski K; Schorb E; Illerhaus G
BMC Cancer; 2022 Sep; 22(1):971. PubMed ID: 36088292
[TBL] [Abstract][Full Text] [Related]
52. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
[TBL] [Abstract][Full Text] [Related]
53. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
54. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
55. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
[TBL] [Abstract][Full Text] [Related]
56. Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL).
Kim KH; Lee JH; Lee M; Kim HG; Do YR; Park Y; Oh SY; Shin HJ; Kim WS; Park SK; Kong JH; Park MR; Yang DH; Kwak JY; Kang HJ; Mun YC; Won JH
Cancer Res Treat; 2023 Jan; 55(1):304-313. PubMed ID: 35381164
[TBL] [Abstract][Full Text] [Related]
57. Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.
Miyao K; Sakemura R; Imai K; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Int J Hematol; 2014 Aug; 100(2):152-8. PubMed ID: 24947495
[TBL] [Abstract][Full Text] [Related]
58. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
59. Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
Tutschka PJ; Bilgrami SA; Feingold JM; Edwards RL; Bona RD; Naqvi B; Clive J
Acta Haematol; 2001; 105(4):222-32. PubMed ID: 11528096
[TBL] [Abstract][Full Text] [Related]
60. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
